



## EnhanceMed™ Quarterly Clinical Update

*Highlighting Current Research and Market Updates Affecting Behavioral Health Medical Practitioners*

**2/8/2010 Canadian Study Warns Paroxetine and Fluoxetine Should Not Be Used by Women Taking Tamoxifen:** The Study published in the British Medical Journal provides evidence that some SSRI antidepressants neutralize tamoxifen's beneficial effect in treating breast cancer by interfering with CYP2D6. Paroxetine is a strong inhibitor of the CYP2D6 enzyme that converts tamoxifen to its active metabolite. In women who have had breast cancer and are now taking tamoxifen to prevent a recurrence, citalopram or venlafaxine should be considered for depression and/or hot flashes instead. For every 20 women taking Paxil and tamoxifen together, if Paxil is taken the entire time tamoxifen is used, there will be one additional death for every seven women treated with both drugs. Although fluoxetine, another inhibitor of CYP2D6, did not increase death risk in the study, the researchers warn this may be due to the relatively small numbers of women on this drug in their population. BMJ 2010;340:c693

**2/2/2010 Lancet Formally Retracts Paper Linking Vaccine to Autism:** The Lancet formally retracted an article that previously sparked a fierce debate. The 1998 Andrew Wakefield study linked the vaccine for mumps, measles, and rubella to autism, which resulted in a subsequent decrease in vaccinations and a jump in measles cases. Additional studies have found no link between the vaccine and autism.

**1/29/2010 Zyprexa (olanzapine): Use in Adolescents:** Eli Lilly and the FDA notified health care professionals of changes to the prescribing information for Zyprexa related to its indication for use in adolescents (ages 13-17) for treatment of schizophrenia and bipolar I disorder [manic or mixed episodes]. The revised labeling indicates using caution when deciding among treatments available for adolescents due to the increased potential for weight gain and hyperlipidemia. Additionally, it noted the need for a comprehensive treatment program in pediatric patients to include psychological, educational and social measures for patients with schizophrenia and bipolar disorder. Lastly, it noted effectiveness and safety of Zyprexa have not been established in pediatric patients younger than 13 years of age.

**1/13/2010 Moban Market Withdrawal:** Endo Pharmaceuticals has discontinued manufacturing Moban (molindone hcl) tablets in all strengths (5mg, 10mg, 25mg, and 50mg). Supplies are anticipated to be depleted by June 30, 2010. This action is not the result of any safety or efficacy issues. Rather, it was a business decision. For additional information you can call Endo at 1-800-462-ENDO.

**12/2/2009 Norpramin Safety information:** Sanofi-Aventis notified health care professionals about updated safety information for the antidepressant Norpramin (desipramine hydrochloride). The section on overdosage now notes that overdoses of this drug have resulted in a higher death rate than overdoses of other tricyclic antidepressants. Also, a new warning in the labeling now says to use extreme caution when giving this drug to patients with a family history of sudden death, cardiac dysrhythmias, and cardiac conduction disturbances. The warning also notes that in some patients, the cardiac dysrhythmias and death were preceded by seizures. For additional questions, you may call Sanofi-Aventis' Medical Information Department at 1-800-633-1610 (option #1) from 9 a.m. to 8 p.m. (EST) Monday-Friday.

**10/28/2009 SATIETY Study Published in JAMA:** The Second-Generation Antipsychotic Treatment Indications, Effectiveness and Tolerability in Youth (SATIETY) study included 205 patients who completed the 12-week study period with treatment of aripiprazole, olanzapine, quetiapine or risperidone. After a median of 10.8 weeks, weight increased by 8.5kg with olanzapine, by 6.1kg with quetiapine, by 5.3kg with risperidone and by 4.4 kg with aripiprazole compared with a weight change of 0.2kg in the untreated comparison group. Significant metabolic changes also occurred with olanzapine, quetiapine and risperidone.

*This is a compilation of some recent news and research that may be of interest to providers. It is for informational and educational purposes only. Although we make every effort to ensure that this material is accurate and up-to-date, it is provided for the convenience of the user and should not be considered definitive. Magellan does not participate in or endorse any of the particular studies contained herein.*

*EnhanceMed Quarterly Update Produced by Magellan Health Services, April 2010*